$1.38 Billion is the total value of Frazier Life Sciences Management, L.P.'s 49 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | HILLEVAX INC | $161,687,732 | -1.0% | 9,781,472 | +0.2% | 11.71% | +15.3% | |
| NEWAMSTERDAM PHARMA COMPANYordinary shares | $125,550,445 | +23.3% | 9,341,551 | 0.0% | 9.09% | +43.6% | ||
| KDNY | CHINOOK THERAPEUTICS INC | $100,599,691 | -11.6% | 4,345,559 | 0.0% | 7.28% | +2.9% | |
| ARQT | Arcutis Biotherapeutics | $95,526,552 | -25.7% | 8,684,232 | 0.0% | 6.92% | -13.5% | |
| MIRM | Mirum Pharmaceuticals, Inc. | $92,719,770 | +23.2% | 3,860,107 | 0.0% | 6.71% | +43.4% | |
| SNDX | Syndax Pharmaceuticals, Inc. | $78,330,659 | -17.0% | 3,708,838 | 0.0% | 5.67% | -3.4% | |
| KRYS | Sell | KRYSTAL BIOTECH INC | $75,689,284 | -4.4% | 945,407 | -5.4% | 5.48% | +11.3% |
| PHAT | Phathom Pharmaceuticals, Inc. | $60,027,065 | -36.4% | 8,407,152 | 0.0% | 4.35% | -25.9% | |
| VRNA | Buy | VERONA PHARMA PLCsponsored ads | $59,122,528 | -19.6% | 2,944,349 | +4.6% | 4.28% | -6.4% |
| PCVX | Vaxcyte, Inc. | $52,374,739 | -21.8% | 1,397,405 | 0.0% | 3.79% | -9.0% | |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $38,618,944 | -30.0% | 2,164,739 | +14.3% | 2.80% | -18.5% |
| KALV | KALVISTA PHARMACEUTICALS INC | $25,457,432 | +16.3% | 3,238,859 | 0.0% | 1.84% | +35.4% | |
| COGT | Buy | COGENT BIOSCIENCES INC | $23,297,272 | -4.4% | 2,159,154 | +2.4% | 1.69% | +11.3% |
| ALPN | ALPINE IMMUNE SCIENCES INC | $23,050,044 | +5.0% | 2,985,757 | 0.0% | 1.67% | +22.4% | |
| Buy | TYRA BIOSCIENCES INC | $22,840,452 | +126.4% | 1,421,310 | +7.1% | 1.65% | +163.8% | |
| CRNX | CRINETICS PHARMACEUTICALS IN | $22,722,057 | -12.2% | 1,414,823 | 0.0% | 1.64% | +2.2% | |
| TARS | Tarsus Pharmaceuticals, Inc. | $22,469,214 | -14.3% | 1,787,527 | 0.0% | 1.63% | -0.1% | |
| Buy | THESEUS PHARMACEUTICALS INC | $19,963,963 | +186.7% | 2,248,194 | +60.8% | 1.44% | +233.7% | |
| ANAB | ANAPTYSBIO INC | $19,577,472 | -29.8% | 899,700 | 0.0% | 1.42% | -18.2% | |
| BBIO | New | BRIDGEBIO PHARMA INC | $19,425,957 | – | 1,171,650 | +100.0% | 1.41% | – |
| RVMD | New | REVOLUTION MEDICINES INC | $18,508,123 | – | 854,484 | +100.0% | 1.34% | – |
| New | ENLIVEN THERAPEUTICS INC | $18,198,528 | – | 830,983 | +100.0% | 1.32% | – | |
| ACAD | ACADIA PHARMACEUTICALS INC | $16,135,101 | +18.2% | 857,338 | 0.0% | 1.17% | +37.6% | |
| GRTS | GRITSTONE BIO INC | $14,351,327 | -19.4% | 5,162,348 | 0.0% | 1.04% | -6.1% | |
| MRUS | MERUS N V | $13,735,214 | +18.9% | 746,479 | 0.0% | 0.99% | +38.4% | |
| TRVI | TREVI THERAPEUTICS INC | $12,327,642 | -4.1% | 6,663,590 | 0.0% | 0.89% | +11.6% | |
| MGNX | New | MACROGENICS INC | $12,211,973 | – | 1,703,204 | +100.0% | 0.88% | – |
| REPL | Sell | REPLIMUNE GROUP INC | $12,128,217 | -52.1% | 686,762 | -26.3% | 0.88% | -44.3% |
| VECT | Buy | VECTIVBIO HLDG AG | $11,628,911 | +1.3% | 1,352,199 | +1.4% | 0.84% | +17.9% |
| CERE | CEREVEL THERAPEUTICS HLDNG I | $9,585,270 | -22.7% | 393,000 | 0.0% | 0.69% | -10.0% | |
| IMVT | Immunovant, Inc. | $9,085,122 | -12.6% | 585,759 | 0.0% | 0.66% | +1.9% | |
| STRO | SUTRO BIOPHARMA INC | $8,207,333 | -42.8% | 1,776,479 | 0.0% | 0.59% | -33.4% | |
| MORF | New | MORPHIC HLDG INC | $8,063,994 | – | 214,240 | +100.0% | 0.58% | – |
| ARVN | ARVINAS INC | $7,795,243 | -20.1% | 285,331 | 0.0% | 0.56% | -7.1% | |
| RNA | AVIDITY BIOSCIENCES INC | $7,675,000 | -30.8% | 500,000 | 0.0% | 0.56% | -19.4% | |
| NTLA | INTELLIA THERAPEUTICS INC | $7,591,303 | +6.8% | 203,684 | 0.0% | 0.55% | +24.4% | |
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $6,894,217 | -3.2% | 3,746,857 | 0.0% | 0.50% | +12.6% | |
| AVTE | New | AEROVATE THERAPEUTICS INC | $6,819,679 | – | 338,110 | +100.0% | 0.49% | – |
| PRTA | PROTHENA CORP PLC | $6,199,313 | -19.6% | 127,900 | 0.0% | 0.45% | -6.3% | |
| ZYMEWORKS INC | $5,514,400 | +15.0% | 610,000 | 0.0% | 0.40% | +33.9% | ||
| SLN | SILENCE THERAPEUTICS PLCads | $5,463,273 | -59.3% | 881,173 | 0.0% | 0.40% | -52.6% | |
| ALLK | Sell | ALLAKOS INC | $4,951,444 | -87.7% | 1,112,684 | -76.8% | 0.36% | -85.7% |
| BLUE | BLUEBIRD BIO INC | $4,581,607 | -54.0% | 1,440,757 | 0.0% | 0.33% | -46.5% | |
| EWTX | New | EDGEWISE THERAPEUTICS INC | $4,552,015 | – | 682,461 | +100.0% | 0.33% | – |
| PASG | Passage Bio, Inc. | $3,597,997 | -30.6% | 3,756,915 | 0.0% | 0.26% | -18.9% | |
| ADCT | New | ADC THERAPEUTICS SA | $3,211,709 | – | 1,647,030 | +100.0% | 0.23% | – |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $2,138,810 | -53.2% | 264,377 | -8.9% | 0.16% | -45.4% |
| NEWAMSTERDAM PHARMA COMPANY*w exp 11/22/202 | $920,613 | +112.0% | 500,333 | 0.0% | 0.07% | +148.1% | ||
| NABRIVA THERAPEUTICS PLC | $29,741 | -7.6% | 17,025 | 0.0% | 0.00% | 0.0% | ||
| APTX | Exit | APTINYX INC | $0 | – | -1,883,244 | -100.0% | -0.03% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -605,141 | -100.0% | -0.10% | – |
| Exit | IMAGO BIOSCIENCES INC | $0 | – | -3,987,207 | -100.0% | -8.91% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS INC | 7 | Q3 2023 | 17.0% |
| MIRUM PHARMACEUTICALS INC | 7 | Q3 2023 | 13.6% |
| PHATHOM PHARMACEUTICALS INC | 7 | Q3 2023 | 8.6% |
| KRYSTAL BIOTECH INC | 7 | Q3 2023 | 7.6% |
| SYNDAX PHARMACEUTICALS INC | 7 | Q3 2023 | 6.3% |
| VAXCYTE INC | 7 | Q3 2023 | 4.8% |
| CRINETICS PHARMACEUTICALS IN | 7 | Q3 2023 | 3.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 3.2% |
| TARSUS PHARMACEUTICALS INC | 7 | Q3 2023 | 2.5% |
| KALVISTA PHARMACEUTICALS INC | 7 | Q3 2023 | 2.1% |
View Frazier Life Sciences Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-07 |
| 13F-HR | 2023-02-03 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-16 |
View Frazier Life Sciences Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.